Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Spruce Biosciences (SPRB) stock

Learn how to easily invest in Spruce Biosciences stock.

Spruce Biosciences, Inc

Spruce Biosciences, Inc is a biotechnology business based in the US. Spruce Biosciences shares (SPRB) are listed on the NASDAQ and all prices are listed in US Dollars. Spruce Biosciences employs 19 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Spruce Biosciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SPRB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Spruce Biosciences stock price (NASDAQ: SPRB)

Use our graph to track the performance of SPRB stocks over time.

Spruce Biosciences shares at a glance

Information last updated 2021-07-22.
Latest market close$14.13
52-week range$9.20 - $31.25
50-day moving average $11.14
200-day moving average $16.59
Wall St. target price$33.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Spruce Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Spruce Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Spruce Biosciences price performance over time

Historical closes compared with the close of $14.13 from 2021-05-28

1 week (2021-07-15) N/A
1 month (2021-06-25) 28.45%
3 months (2021-04-26) -17.13%
6 months (2021-01-22) N/A
1 year (2020-07-22) N/A
2 years (2019-07-22) N/A
3 years (2018-07-22) N/A
5 years (2016-07-22) N/A

Spruce Biosciences financials

Gross profit TTM $0
Return on assets TTM -22.09%
Return on equity TTM -49.69%
Profit margin 0%
Book value $6.04
Market capitalisation $217.9 million

TTM: trailing 12 months

Shorting Spruce Biosciences shares

There are currently 510,049 Spruce Biosciences shares held short by investors – that's known as Spruce Biosciences's "short interest". This figure is 5.5% up from 483,344 last month.

There are a few different ways that this level of interest in shorting Spruce Biosciences shares can be evaluated.

Spruce Biosciences's "short interest ratio" (SIR)

Spruce Biosciences's "short interest ratio" (SIR) is the quantity of Spruce Biosciences shares currently shorted divided by the average quantity of Spruce Biosciences shares traded daily (recently around 88704.173913043). Spruce Biosciences's SIR currently stands at 5.75. In other words for every 100,000 Spruce Biosciences shares traded daily on the market, roughly 5750 shares are currently held short.

To gain some more context, you can compare Spruce Biosciences's short interest ratio against those of similar companies.

However Spruce Biosciences's short interest can also be evaluated against the total number of Spruce Biosciences shares, or, against the total number of tradable Spruce Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spruce Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Spruce Biosciences shares in existence, roughly 20 shares are currently held short) or 0.1069% of the tradable shares (for every 100,000 tradable Spruce Biosciences shares, roughly 107 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Spruce Biosciences.

Find out more about how you can short Spruce Biosciences stock.

Spruce Biosciences share dividends

We're not expecting Spruce Biosciences to pay a dividend over the next 12 months.

Spruce Biosciences overview

Spruce Biosciences, Inc. , a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc.

Frequently asked questions

What percentage of Spruce Biosciences is owned by insiders or institutions?
Currently 0.006% of Spruce Biosciences shares are held by insiders and 101.633% by institutions.
How many people work for Spruce Biosciences?
Latest data suggests 19 work at Spruce Biosciences.
When does the fiscal year end for Spruce Biosciences?
Spruce Biosciences's fiscal year ends in December.
Where is Spruce Biosciences based?
Spruce Biosciences's address is: 2001 Junipero Serra Boulevard, Daly City, CA, United States, 94014
What is Spruce Biosciences's ISIN number?
Spruce Biosciences's international securities identification number is: US85209E1091

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site